The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1329
Intravenous Ibuprofen (Caldolor)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An intraveneous (IV) formulation of ibuprofen (Caldolor – Cumberland) was recently approved by the FDA for use in adults. It can be administered alone for treatment of mild to moderate pain or as an adjunct to opioid analgesics for moderate to severe pain. It is also approved for reduction of fever.

NSAIDS FOR PAIN — Use of a nonsteroidal anti-inflammatory drug (NSAID) in addition to an opioid analgesic for management of postoperative pain has been shown to improve pain control and reduce opioid use,1 but administration of an oral NSAID may not be possible during or immediately after surgery. Ketorolac (Toradol, and others), the only other NSAID available in an injectable formulation for use as an analgesic, can cause severe gastrointestinal toxicity and is not recommended for more than 5 days’ use. Indomethacin is available for IV use in closure of a patent ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Intravenous Ibuprofen (Caldolor)
Article code: 1329c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian